| CLDN18.2 is expressed in normal gastric mucosal epithelial cells and in other solid tumors such as stomach, colon cancer and pancreas.It is a potential target for the treatment of digestive system tumors at present.Targeted therapy for CLDN18.2 mainly includes monoclonal antibody (mAb), CAR-T cell therapy, bispecific antibody (BsAb) and antibody-coupled drug (ADC).At present, many drugs targeting CLDN18.2 have entered clinical trials, among which Zolbetuximab has made the fastest progress.This paper reviews CLDN18.2 and its clinical research progress in advanced gastric cancer. |
